David Hart
Internal Medicine · Morrow, GANPI 1669455150
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,228 and has fallen 98.8% since, to $15 in 2025.
Across 67 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$205
- GSK$200
- Radius Health, Inc.$139
- Mylan Specialty L.p.$91
- Astellas Pharma US Inc$81
- Sanofi-aventis U.S. LLC$68
- plus $489 from 18 others
What the payments were for
- Food & beverage$1,18293%
- Education$907%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $205 |
| GSK | 8 | $200 |
| Radius Health, Inc. | 11 | $139 |
| Mylan Specialty L.p. | 1 | $91 |
| Astellas Pharma US Inc | 4 | $81 |
| Sanofi-aventis U.S. LLC | 3 | $68 |
| Novo Nordisk | 5 | $66 |
| Boehringer Ingelheim | 3 | $52 |
| Amgen | 3 | $45 |
| Pfizer | 3 | $45 |
| AbbVie(2 entities) | 3 | $41 |
| Novartis | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Genentech USA, Inc. | 1 | $24 |
| Lilly USA, LLC | 2 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Neos Therapeutics, LP | 1 | $19 |
| Insulet Corporation | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Merck | 1 | $13 |
| Circassia Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
| Mannkind Corporation | 1 | $11 |
| Companion Medical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
How this compares
$1,273 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 107 | $123,486 |
| EliquisApixaban | 91 | $105,552 |
| OzempicSemaglutide | 63 | $101,542 |
| CompleraEmtricita/Rilpivirine/Tenof Df | 12 | $43,478 |
| XareltoRivaroxaban | 27 | $29,769 |
| LinzessLinaclotide | 34 | $28,564 |
| TrulicityDulaglutide | 20 | $22,836 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $19,822 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 151 | $19,055 |
| FarxigaDapagliflozin Propanediol | 14 | $17,793 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $17,711 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 438 | $15,954 |
| MyrbetriqMirabegron | 11 | $15,810 |
| MounjaroTirzepatide | 13 | $13,546 |
| Pioglitazone-MetforminPioglitazone Hcl/Metformin Hcl | 51 | $7,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $52 | $123,486107 claims |
| PfizerEliquis | $45 | $105,55291 claims |
| Novo NordiskOzempic, Novolog | $66 | $103,93481 claims |
| Johnson & JohnsonComplera, Xarelto | $16 | $73,24739 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $24 | $36,38233 claims |
| AbbVieLinzess | $41 | $28,56434 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $200 | $26,81730 claims |
| AstraZenecaFarxiga | $205 | $17,79314 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $15,81011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Morrow
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.